QCG
GBT

Quadrant Capital Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Quadrant Capital Group’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28
Closed -$2K – 2913
2022
Q3 		$2K Hold
28
– – ﹤0.01% 2455
2022
Q2 		$1K Sell
28
-25
-47% -$732 ﹤0.01% 2502
2022
Q1 		$2K Sell
53
-4
-7% -$120 ﹤0.01% 2221
2021
Q4 		$2K Buy
57
+29
+104% +$898 ﹤0.01% 2211
2021
Q3 		$1K Buy
+28
New +$823 ﹤0.01% 2452
2021
Q2 		– Sell
-3
Closed – – 2633
2021
Q1 		$0 Hold
3
– – ﹤0.01% 2493
2020
Q4 		$0 Sell
3
-17
-85% -$838 ﹤0.01% 2410
2020
Q3 		$1K Buy
+20
New +$1.27K ﹤0.01% 2114
2020
Q2 		– Sell
-3
Closed – – 2463
2020
Q1 		$0 Buy
+3
New +$201 ﹤0.01% 2318
2019
Q3 		– Sell
-347
Closed -$18K – 2425
2019
Q2 		$18K Buy
+347
New +$19.9K ﹤0.01% 1670

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Quadrant Capital Group's GBT Position: Q4 2022 in Review

Quadrant Capital Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 28 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in GBT in Q2 2019 and held it in 10 quarters. The position peaked at $18K in Q2 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Quadrant Capital Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 28 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2K.
  • Quadrant Capital Group first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 10 quarters.
  • Quadrant Capital Group's Global Blood Therapeutics, Inc. position peaked at $18K in Q2 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.